Literature DB >> 28536834

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.

C Chiesa1, K Sjogreen Gleisner2, G Flux3, J Gear3, S Walrand4, K Bacher5, U Eberlein6, E P Visser7, N Chouin8, M Ljungberg2, M Bardiès9, M Lassmann6, L Strigari10, M W Konijnenberg11.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28536834     DOI： 10.1007/s00259-017-3707-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  24 in total

1.  The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Authors:  Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-16       Impact factor: 9.236

2.  Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

Authors:  L Bianchi; A Baroli; G Lomuscio; L Pedrazzini; A Pepe; L Pozzi; C Chiesa
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 2.346

3.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

4.  Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.

Authors:  Robert Dorn; Juergen Kopp; Harry Vogt; Peter Heidenreich; Robert G Carroll; Seza A Gulec
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

5.  Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.

Authors:  Silvano Gnesin; Laurent Canetti; Salim Adib; Nicolas Cherbuin; Marina Silva Monteiro; Pierre Bize; Alban Denys; John O Prior; Sebastien Baechler; Ariane Boubaker
Journal:  J Nucl Med       Date:  2016-06-15       Impact factor: 10.057

6.  Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.

Authors:  Peter Kletting; Thomas Kull; Christian Maaß; Noeen Malik; Markus Luster; Ambros J Beer; Gerhard Glatting
Journal:  J Nucl Med       Date:  2015-12-17       Impact factor: 10.057

7.  Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Authors:  Frederik A Verburg; Heribert Hänscheid; Johannes Biko; Maria C Hategan; Michael Lassmann; Michael C Kreissl; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-24       Impact factor: 9.236

8.  Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.

Authors:  Hendrik Bergsma; Mark W Konijnenberg; Wouter A van der Zwan; Boen L R Kam; Jaap J M Teunissen; Peter P Kooij; Katya A L Mauff; Eric P Krenning; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-10       Impact factor: 9.236

9.  Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Douglas Van Nostrand; Frank Atkins; Kenneth Burman; Jacqueline Jonklaas; Mihriye Mete; Leonard Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  2011-08-17       Impact factor: 5.958

Review 10.  Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.

Authors:  Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia
Journal:  Front Oncol       Date:  2014-08-19       Impact factor: 6.244
View more
  15 in total

Review 1.  Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Authors:  Makoto Hosono
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  Dosimetry in clinical radionuclide therapy: the devil is in the detail.

Authors:  Francesco Giammarile; Kristoff Muylle; Roberto Delgado Bolton; Jolanta Kunikowska; Uwe Haberkorn; Wim Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-10       Impact factor: 9.236

3.  Quantitative 166Ho-microspheres SPECT derived from a dual-isotope acquisition with 99mTc-colloid is clinically feasible.

Authors:  M Stella; Ajat Braat; Mgeh Lam; Hwam de Jong; R van Rooij
Journal:  EJNMMI Phys       Date:  2020-07-14

4.  From fixed activities to personalized treatments in radionuclide therapy: lost in translation?

Authors:  G D Flux; K Sjogreen Gleisner; C Chiesa; M Lassmann; N Chouin; J Gear; M Bardiès; S Walrand; K Bacher; U Eberlein; M Ljungberg; L Strigari; E Visser; M W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-27       Impact factor: 9.236

Review 5.  Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review.

Authors:  Daphne Merel Valerie Huizing; Berlinda Jantina de Wit-van der Veen; Marcel Verheij; Marcellus Petrus Maria Stokkel
Journal:  EJNMMI Res       Date:  2018-08-29       Impact factor: 3.138

6.  Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate.

Authors:  Lore Santoro; Erick Mora-Ramirez; Dorian Trauchessec; Soufiane Chouaf; Pierre Eustache; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Manuel Bardiès; Emmanuel Deshayes
Journal:  EJNMMI Res       Date:  2018-11-29       Impact factor: 3.138

Review 7.  Clinical Perspectives of Theranostics.

Authors:  Shozo Okamoto; Tohru Shiga; Nagara Tamaki
Journal:  Molecules       Date:  2021-04-13       Impact factor: 4.411

8.  177 Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction.

Authors:  Daphne M V Huizing; Michiel Sinaasappel; Marien C Dekker; Marcel P M Stokkel; Berlinda J de Wit-van der Veen
Journal:  J Appl Clin Med Phys       Date:  2020-08-13       Impact factor: 2.102

Review 9.  The physics of radioembolization.

Authors:  Remco Bastiaannet; S Cheenu Kappadath; Britt Kunnen; Arthur J A T Braat; Marnix G E H Lam; Hugo W A M de Jong
Journal:  EJNMMI Phys       Date:  2018-11-02

10.  EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.

Authors:  Mark Konijnenberg; Ken Herrmann; Carsten Kobe; Frederik Verburg; Cecilia Hindorf; Roland Hustinx; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-15       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.